RXDX News and Press, Prometheus Biosciences Inc. From 10/25/22

Summary These articles are intended to provide readers with equity investment subjects [stocks, ETFs, REITs] which probably may experience rising market prices in next 3-5 months: Near-term expectations only. They are drawn from a 3,000+ equity population updated daily which infer...

- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF - - PRA052 is the second clinical candidate identified using the Prometheus360™ platform with one ...

By revenue, Pfizer (NYSE: PFE) is far and away the world's largest pharmaceutical company. Even if you ignore record-breaking sales of its COVID-19 vaccine, Pfizer is a pharma giant that can easily overshadow a pre-commercial biotechnology company like Prometheus Biosciences (...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. The new National Biotechnology and Biomanufacturing I...

The following slide deck was published by Prometheus Biosciences, Inc. in conjunction with this event. For further details see: Prometheus Biosciences (RXDX) Investor Presentation - Slideshow

Summary 88% technical buy signals. 8 new highs and up 13.65% in the last month. Price targets from 50-75. The Chart of the Day belongs to the biotechnology company Prometheus Biosciences ( RXDX ). I found the stock by sorting Barchart's All Time High list fir...

SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the...

Prometheus Biosciences press release ( NASDAQ: RXDX ): Q2 GAAP EPS of -$0.86 beats by $0.06 . Revenue of $1.26M (+320.0% Y/Y) beats by $0.8M . For further details see: Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0...

- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022 - - Bioavailability greater than 80% achieved upon completion of PRA023 subcutaneous bridging study - - Unveiled Prometheus’ second precision candidate, PRA0...

Shares of Prometheus Biosciences ( NASDAQ: RXDX ) rose as much as 11.3% to $34.23 in Wednesday trading after Goldman Sachs initiated the company with a buy rating. Goldman Sachs analyst Chris Shibutani gave RXDX stock a price target of $51, implying a 65.8% upside to RXD...